[go: up one dir, main page]

WO2017203532A8 - Agents à utiliser pour le traitement de tumeurs résistantes aux médicaments et du cancer du sein triple négatif - Google Patents

Agents à utiliser pour le traitement de tumeurs résistantes aux médicaments et du cancer du sein triple négatif Download PDF

Info

Publication number
WO2017203532A8
WO2017203532A8 PCT/IL2017/050586 IL2017050586W WO2017203532A8 WO 2017203532 A8 WO2017203532 A8 WO 2017203532A8 IL 2017050586 W IL2017050586 W IL 2017050586W WO 2017203532 A8 WO2017203532 A8 WO 2017203532A8
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
triple negative
negative breast
agents
drug resistant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2017/050586
Other languages
English (en)
Other versions
WO2017203532A1 (fr
Inventor
Sima Lev
Anna Mueller
Nandini VERMA
Charu KOTHARI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of WO2017203532A1 publication Critical patent/WO2017203532A1/fr
Publication of WO2017203532A8 publication Critical patent/WO2017203532A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des polythérapies qui font intervenir un agent qui régule à la baisse une quantité et/ou une activité d'un récepteur qui est exprimé sur la surface de cellules tumorales d'un sujet et un agent qui régule à la baisse de manière spécifique une quantité et/ou une activité d'au moins un membre de la famille Fak à utiliser pour le traitement du cancer, plus particulièrement le cancer du sein, et plus particulièrement le cancer du sein triple négatif. L'invention concerne également des compositions pharmaceutiques comprenant les agents des polythérapies, ainsi qu'une méthode ex vivo pour établir un pronostic du cancer du sein triple négatif, et un kit pour déterminer ledit pronostic.
PCT/IL2017/050586 2016-05-25 2017-05-25 Agents à utiliser pour le traitement de tumeurs résistantes aux médicaments et du cancer du sein triple négatif Ceased WO2017203532A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL245861 2016-05-25
IL245861A IL245861A0 (en) 2016-05-25 2016-05-25 Use of substances to treat drug-resistant tumors

Publications (2)

Publication Number Publication Date
WO2017203532A1 WO2017203532A1 (fr) 2017-11-30
WO2017203532A8 true WO2017203532A8 (fr) 2018-03-15

Family

ID=57883834

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2017/050586 Ceased WO2017203532A1 (fr) 2016-05-25 2017-05-25 Agents à utiliser pour le traitement de tumeurs résistantes aux médicaments et du cancer du sein triple négatif

Country Status (2)

Country Link
IL (1) IL245861A0 (fr)
WO (1) WO2017203532A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020024825A1 (fr) * 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Méthode de traitement du cancer à l'aide d'une combinaison d'inhibiteur de fak/alk/ros1 et d'inhibiteur d'egfr
WO2020210537A1 (fr) * 2019-04-09 2020-10-15 Envisagenics, Inc. Molécules spécifiques au cancer et leurs méthodes d'utilisation

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5189178A (en) 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP1228766A1 (fr) * 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Phosphorylation de PYK2 par HER3 induit l'invasion de tumeurs
EP2509592A1 (fr) * 2009-12-07 2012-10-17 Boehringer Ingelheim International GmbH Bibw 2992 pour utilisation dans le traitement du cancer du sein triple négatif
CA2787225A1 (fr) 2010-01-12 2011-07-21 Nestec S.A. Procedes pour predire la reponse d'un cancer du sein triple negatif a une therapie
WO2016029002A2 (fr) 2014-08-22 2016-02-25 Clovis Oncology, Inc. Inhibiteurs du récepteur du facteur de croissance

Also Published As

Publication number Publication date
IL245861A0 (en) 2016-09-04
WO2017203532A1 (fr) 2017-11-30

Similar Documents

Publication Publication Date Title
WO2016196298A8 (fr) Méthodes diagnostiques et thérapeutiques pour le cancer
EP4435112A3 (fr) Compositions et procédés de criblage de tumeurs solides
MY180365A (en) Markers of tumor cell response to anti-cancer therapy
WO2016106404A3 (fr) Méthodes et compositions destinées à traiter les tumeurs malignes associées à une mutation de kras
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
WO2016196776A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
WO2016004305A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
PH12017501857A1 (en) Pd-l1 antagonist combination treatments
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
EA201991622A1 (ru) Комплексная терапия для лечения рака
WO2019090347A8 (fr) Inhibiteurs de la voie de l'adénosine pour le traitement du cancer
MX2014005800A (es) Mutaciones del receptor notch humano y su uso.
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
WO2015171558A3 (fr) Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de rorγ et pour le traitement de maladie
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
WO2019175260A3 (fr) Oligonucléotides modifiés et méthodes d'utilisation dans les tauopathies
MX2021003214A (es) Metodos terapeuticos y de diagnostico para el cancer de vejiga.
WO2017203532A8 (fr) Agents à utiliser pour le traitement de tumeurs résistantes aux médicaments et du cancer du sein triple négatif
EP3303363A4 (fr) Hétérogénéité génomique intra-patients de cellules tumorales circulantes (ctc) uniques associée à l'hétérogénéité de ctc phénotypique dans le cancer de la prostate métastasique androgéno-indépendant (mcrpc)
WO2015193462A3 (fr) Méthode de prédiction d'une dose d'esa personnalisée pour le traitement de l'anémie
MX2020006388A (es) Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.
WO2015181555A8 (fr) Établissement de profils d'expression pour les cancers traités par thérapie anti-angiogénique
EP3740755C0 (fr) Utilisation de la protéine tas1r3 comme marqueur à des fins thérapeutiques, diagnostiques, et/ou à des fins de pronostic pour des tumeurs exprimant cette protéine
WO2015036643A3 (fr) Marqueur pour la prédiction de métastases d'un cancer du sein
EP1968981A4 (fr) Procédé de traitement de tumeurs avec des azaxanthones

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17733047

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17733047

Country of ref document: EP

Kind code of ref document: A1